Structural insights into zinc homeostasis
锌稳态的结构见解
基本信息
- 批准号:10315746
- 负责人:
- 金额:$ 6.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAndrogen ReceptorApoptosisBindingBiochemistryBiological AssayBiopsyBrainBreastCastrationCatalysisCell CommunicationCell Culture TechniquesCell ProliferationCellular biologyCharacteristicsChargeCrystallizationCytosolDetergentsDiabetes MellitusDietary ZincDrug DesignElectron MicroscopyElementsEnvironmentFamilyFamily memberFluorescence SpectroscopyFoundationsFutureGTP-Binding ProteinsGenomeGoalsHandHomeostasisHumanImmunityIn VitroIndividualInsulinIonsLengthLipidsLiteratureMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMammalian CellMapsMeasuresMediatingMembraneMembrane ProteinsMessenger RNAMetalsMolecularMolecular StructureMutagenesisMutateNerve DegenerationNeurodegenerative DisordersPathway interactionsPharmacologyPhasePhysiological ProcessesPlayProcessProductionProstateProteinsProtocols documentationResearchResistanceResolutionRoleSignal TransductionSite-Directed MutagenesisSpecificityStructural ProteinStructureTestingTestosteroneTherapeuticTherapeutic InterventionTissue SampleWorkZincbasecancer cellcryogenicscytotoxicdietaryeggelectron diffractionexperimental studyimmune functioninsightinsulin secretionmembernanomolarneurotransmissionnovelnovel therapeutic interventionparticleprostate cancer cellprotein structureproteoliposomesproteostasissolutestopped-flow fluorescencetooltumoruptake
项目摘要
Project Summary / Abstract
The Zrt-, Irt-like Protein (ZIP, or Solute Carrier 39 (SLC39)) family of membrane proteins mediate zinc influx1.
Zinc homeostasis is a critical regulator of a variety of physiological processes, including immune function, insulin
secretion, and cell communication, and plays key roles in protein structure and catalysis2. Because both excess
and deficient zinc levels are cytotoxic, zinc homeostasis is tightly controlled in mammalian cells via an abundant
network of membrane proteins that act as zinc importers (ZIP / SLC39 family) or zinc exporters (ZnT / SLC30
family). Zinc homeostasis proteins are potential pharmacological targets in neurodegenerative disorders and
cancer, but progress is hampered by a lack of structural and mechanistic information. No full length mammalian
structures of ZIP family members have been solved and no in vitro functional assays exist. ZIP9 (SLC39A9)
represents a novel treatment avenue for prostate cancer3. The prostate has the highest concentration of zinc in
the body, which promotes apoptosis and helps maintain low levels of cellular proliferation. In prostate cancer,
zinc levels decrease, leading to tumor proliferation4. Prostate zinc levels cannot be rescued with dietary
supplements5,6. Recently, ZIP9 was identified as a membrane Androgen Receptor (mAR) which mediates
testosterone-induced apoptosis7. ZIP9 is upregulated in prostate cancer, but to realize its potential as a
pharmacological target a full structural and functional characterization is required. My objective is to elucidate
the structure and mechanism of ZIP9. Aim 1 is to develop a proteoliposome-based functional assay using
stopped-flow fluorescence spectroscopy and site-directed mutagenesis to characterize the mechanism of ZIP9.
Aim 2 is to determine the structural basis of zinc influx by ZIP9 using Microcrystal Electron Diffraction (MicroED).
Aim 3 is to examine ZIP9's mAR characteristics by determining the molecular and structural basis of its
interactions with testosterone and G proteins using biochemistry and high resolution single particle cryogenic
electron microscopy (cryoEM). This research will unravel the mechanism of ZIP-mediated Zn2+ influx and clarify
ZIP9's putative role as a membrane Androgen Receptor, broadening our understanding of zinc homeostasis and
paving the way for the use of ZIPs as a pharmacological target in prostate cancer and beyond.
项目总结/摘要
Zrt-,Irt-样蛋白(ZIP,或溶质载体39(SLC 39))家族的膜蛋白介导锌流入1。
锌稳态是多种生理过程的关键调节剂,包括免疫功能、胰岛素、胰岛素抵抗等。
分泌和细胞通讯,并在蛋白质结构和催化中发挥关键作用2。因为这两种过度
缺乏锌水平是细胞毒性的,锌稳态在哺乳动物细胞中通过丰富的
作为锌输入者(ZIP /SLC 39家族)或锌输出者(ZnT /SLC 30)的膜蛋白网络
家庭)。锌稳态蛋白是神经退行性疾病的潜在药理学靶点,
癌症,但进展受到缺乏结构和机制信息的阻碍。无全长哺乳动物
ZIP家族成员的结构已经被解决,并且不存在体外功能测定。ZIP9(SLC39A9)
代表了前列腺癌的一种新的治疗途径3。前列腺中锌的浓度最高,
它能促进细胞凋亡并有助于维持低水平的细胞增殖。在前列腺癌中,
锌水平下降,导致肿瘤增殖4。前列腺锌水平不能用饮食来挽救
5,6.最近,ZIP 9被鉴定为膜雄激素受体(mAR),其介导
睾酮诱导的睾丸激素缺乏症7. ZIP 9在前列腺癌中上调,但要实现其作为治疗前列腺癌的潜力,
药理学靶点需要完整的结构和功能表征。我的目的是阐明
ZIP 9的结构和机制。目的1是开发一种基于蛋白脂质体的功能测定方法,
停流荧光光谱法和定点诱变来表征ZIP 9的机制。
目的2是利用微晶电子衍射(MicroED)确定ZIP 9内流锌的结构基础。
目的3是通过确定ZIP 9的分子和结构基础来检查ZIP 9的mAR特征。
使用生物化学和高分辨率单粒子低温与睾酮和G蛋白的相互作用
电子显微镜(cryoEM)。本研究将阐明ZIP介导的Zn 2+内流机制,
ZIP 9作为膜雄激素受体的假定作用,拓宽了我们对锌稳态的理解,
为ZIPs作为前列腺癌及其他癌症的药理学靶点铺平了道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SARA JEAN WEAVER其他文献
SARA JEAN WEAVER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 6.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)